Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Clinical trials sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., explained in plain language.
Pharmaceutical company manufacturing and developing drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Can a new daily pill quiet the immune attack behind psoriasis?
Disease control Not yet recruitingThis phase 3 trial is testing an experimental daily capsule called TQH3906 in adults with moderate to severe plaque psoriasis. The drug works by blocking a key immune pathway involved in skin inflammation. Researchers are comparing TQH3906 against a placebo and an approved treatm…
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New hope for Hard-to-Treat colorectal cancer: targeted drug combo enters human trials
Disease control Not yet recruitingThis study tests a new drug called TQB2930, which targets the HER2 protein on cancer cells, combined with standard chemotherapy and possibly another drug (bevacizumab). The goal is to find the safest and most effective dose and see if it shrinks tumors in people with advanced col…
Phase: PHASE1, PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for Hard-to-Treat colorectal cancer: targeted drug TQB2102 enters phase 3 trial
Disease control Not yet recruitingThis Phase 3 trial tests a new drug called TQB2102, which delivers chemotherapy directly to HER2-positive cancer cells, in people with advanced colorectal cancer that has stopped responding to standard treatments. About 142 participants will be randomly assigned to receive either…
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC